From the 1960s until the mid-1990s, fluorouracil was the primarychemotherapeutic agent available for the treatment of colorectalcancer. During the past decade, the Food and Drug Administration(FDA) has approved five new drugs for metastatic colorectalcancer. Irinotecan (approved in 1996) and oxaliplatin (2002)are cytotoxic agents that interfere with DNA replication, andcapecitabine (1998) is an oral formulation of fluorouracil.This spring, the monoclonal antibodies bevacizumab and cetuximab,targeting vascular endothelial growth factor and epithelialgrowth factor receptor, respectively, were approved by the FDAfor use in conjunction with cytotoxic regimens.
From the Memorial Sloan-Kettering Cancer Center, New York.
Related Letters:
Cetuximab in Colon Cancer
Holmer A. F., Martin M. J., Costa A. F., Sander G. B., Picon P. D., Schrag D., Chau I., Cunningham D.
Extract |
Full Text |
PDF
N Engl J Med 2004;
351:1575-1576, Oct 7, 2004.
Correspondence
This article has been cited by other articles:
Markman, M.
(2008). Refocusing the Debate: Evidence-Based Clinical Cancer Research Versus Marketplace Reality. J Oncol Pract
4: 231-231
[Full Text]
McFarlane, J., Riggins, J., Smith, T. J.
(2008). SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care. JCO
26: 4200-4204
[Full Text]
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M., Lamont, E. B., Brown, M. L.
(2008). Evaluation of Trends in the Cost of Initial Cancer Treatment. JNCI J Natl Cancer Inst
100: 888-897
[Abstract][Full Text]
Harrington, S. E., Smith, T. J.
(2008). The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?". JAMA
299: 2667-2678
[Abstract][Full Text]
Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L., Topor, M., Meekins, A., Brown, M. L.
(2008). Cost of Care for Elderly Cancer Patients in the United States. JNCI J Natl Cancer Inst
100: 630-641
[Abstract][Full Text]
Lievre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouche, O., Landi, B., Louvet, C., Andre, T., Bibeau, F., Diebold, M.-D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J.-F., Penault-Llorca, F., Laurent-Puig, P.
(2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. JCO
26: 374-379
[Abstract][Full Text]
Goitein, M., Cox, J. D.
(2008). Should Randomized Clinical Trials Be Required for Proton Radiotherapy?. JCO
26: 175-176
[Full Text]
Browman, G. P., Manns, B., Hagen, N., Chambers, C. R., Simon, A., Sinclair, S.
(2008). 6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs. J Oncol Pract
4: 2-7
[Abstract][Full Text]
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., Cortesi, E., Nichelatti, M., Gambacorta, M., Siena, S.
(2007). Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. JCO
25: 3238-3245
[Abstract][Full Text]
Denny, C. C., Emanuel, E. J., Pearson, S. D.
(2007). Why Well-Insured Patients Should Demand Value-Based Insurance Benefits. JAMA
297: 2515-2518
[Full Text]
Lyman, G. H.
(2007). Economics of Cancer Care. J Oncol Pract
3: 113-114
[Full Text]
Kalemkerian, G. P.
(2007). Guidelines Are Never Enough: A Commentary on "When Guidelines Are Not Enough". JCO
25: 1810-1811
[Full Text]
Hillner, B. E., Smith, T. J.
(2007). Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?. JCO
25: 611-613
[Full Text]
Kurian, A. W., Thompson, R. N., Gaw, A. F., Arai, S., Ortiz, R., Garber, A. M.
(2007). A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast Cancer. JCO
25: 634-641
[Abstract][Full Text]
Meropol, N. J., Schulman, K. A.
(2007). Cost of Cancer Care: Issues and Implications. JCO
25: 180-186
[Abstract][Full Text]
Schrag, D., Hanger, M.
(2007). Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey. JCO
25: 233-237
[Abstract][Full Text]
Muss, H. B.
(2006). Targeted Therapy for Metastatic Breast Cancer. NEJM
355: 2783-2785
[Full Text]
Carino, T., Williams, R. D. II, Colbert, A. M., Bridger, P.
(2006). Medicare's Coverage Of Colorectal Cancer Drugs: A Case Study In Evidence Development And Policy. Health Aff (Millwood)
25: 1231-1239
[Abstract][Full Text]
Buckstein, R., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R., Lee, C. R., Taylor, D., Zhang, L., Man, S., Baruchel, S., Stempak, D., Bertolini, F., Crump, M.
(2006). High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. Clin. Cancer Res.
12: 5190-5198
[Abstract][Full Text]
Matsuyama, R., Reddy, S., Smith, T. J.
(2006). Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer. JCO
24: 3490-3496
[Abstract][Full Text]
Schein, P. S., Scheffler, B.
(2006). Barriers to efficient development of cancer therapeutics.. Clin. Cancer Res.
12: 3243-3248
[Full Text]
Kerbel, R. S.
(2006). Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science
312: 1171-1175
[Abstract][Full Text]
Lievre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Cote, J.-F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F., Laurent-Puig, P.
(2006). KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.. Cancer Res.
66: 3992-3995
[Abstract][Full Text]
Gianni, L.
(2006). The cost of life: should it matter to doctors?. Ann Oncol
17: 357-358
[Full Text]
Nadler, E., Eckert, B., Neumann, P. J.
(2006). Do oncologists believe new cancer drugs offer good value?. The Oncologist
11: 90-95
[Abstract][Full Text]
Frieze, D. A, McCune, J. S
(2006). Current Status of Cetuximab for the Treatment of Patients with Solid Tumors. The Annals of Pharmacotherapy
40: 241-250
[Abstract][Full Text]
Jefford, M., Savulescu, J., Thomson, J., Schofield, P., Mileshkin, L., Agalianos, E., Zalcberg, J.
(2005). Medical paternalism and expensive unsubsidised drugs. BMJ
331: 1075-1077
[Full Text]
Emmenegger, U., Kerbel, R. S.
(2005). A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs. Clin. Cancer Res.
11: 7589-7592
[Full Text]
Burtness, B.
(2005). Cetuximab and Cisplatin for Chemotherapy-Refractory Squamous Cell Cancer of the Head and Neck. JCO
23: 5440-5442
[Full Text]
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., Kohne, C.-H.
(2005). Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol
16: 1311-1319
[Abstract][Full Text]
Colleoni, M., Gelber, S., Goldhirsch, A.
(2005). Treatment of advanced breast cancer: the good, the bad and the ugly. Ann Oncol
16: 1219-1221
[Full Text]
Bocci, G., Tuccori, M., Emmenegger, U., Liguori, V., Falcone, A., Kerbel, R. S., Del Tacca, M.
(2005). Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol
16: 1243-1252
[Abstract][Full Text]
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Hunkler, R. J., Hontz, K. M.
(2005). Projecting future drug expenditures--2005. Am J Health Syst Pharm
62: 149-167
[Abstract][Full Text]
DeWilde, L. F., Russell, C.
(2004). The "Welcome to Medicare" Physical: A Great Opportunity for Our Seniors. CA Cancer J Clin
54: 292-294
[Full Text]
Holmer, A. F., Martin, M. J., Costa, A. F., Sander, G. B., Picon, P. D., Schrag, D., Chau, I., Cunningham, D.
(2004). Cetuximab in Colon Cancer. NEJM
351: 1575-1576
[Full Text]
(2004). New Biologic Agent for Metastatic Colorectal Cancer. JWatch Gastroenterology
2004: 3-3
[Full Text]
Erlichman, C., Sargent, D. J.
(2004). New Treatment Options for Colorectal Cancer. NEJM
351: 391-392
[Full Text]
Previous
